In this episode, Ayesha talked about a safety warning issued by the US Food and Drug Administration (FDA) for Secura Bio’s Copiktra (duvelisib), which is a drug used to treat adults with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). The FDA flagged the drug after evaluating long-term survival data, which showed that the drug was associated with a higher risk of serious side effects and a possibly increased risk of death. Ayesha also talked about a new nuclear magnetic resonance (NMR)-based molecular research tool for the assessment of the risk of Long COVID, including multi-organ damage and cardiovascular disease risk. The phenomics tool is being developed by Bruker for research purposes and is based on well-characterized metabolic and proteomic biomarkers associated with Long COVID. Hear more about the tool and how it can help patients receive appropriate treatment interventions early for Long COVID.Read the full articles here: Copiktra Blood Cancer Drug Gets FDA Warning Due to Increased Risk of Serious Side Effects and DeathBruker Develops New Tool for Assessing Long COVID RiskFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured